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Heat shock factor 1 (HSF1) is a transcription factor that plays key roles in cancer, including providing a
mechanism for cell survival under proteotoxic stress. Therefore, inhibition of the HSF1-stress pathway rep-
resents an exciting new opportunity in cancer treatment. We employed an unbiased phenotypic screen to
discover inhibitors of the HSF1-stress pathway. Using this approach we identified an initial hit (1) based on a
4,6-pyrimidine scaffold (2.00 μM). Optimisation of cellular SAR led to an inhibitor with improved potency
(25, 15 nM) in the HSF1 phenotypic assay. The 4,6-pyrimidine 25 was also shown to have high potency
against the CDK9 enzyme (3 nM).
1. Introduction
Heat shock factor 1 (HSF1) is a transcription factor that is the
master regulator of the canonical heat shock response, modu-
lating the expression of hundreds of genes critical to the sur-
vival of the cell.1–3 HSF1 is implicated in the cellular response
to a variety of stressors and plays a key role in oncogenesis
and malignant progression, among other benefits enabling
the cell to cope with the proteotoxic stress resulting from ma-
lignant transformation.4,5
In addition to its transient activation in the classical heat
shock response, HSF1 is frequently upregulated in human
cancers.4,6–8 An HSF1-regulated transcriptional program has
been identified that is specific to highly malignant cells,
overlapping with but distinct from the heat shock response,
which is strongly associated with metastasis and poor sur-
vival in cancer patients.9 There are multiple mechanisms by
which HSF1 has been proposed to facilitate oncogenesis.
HSF1 upregulates proteins involved in diverse biological pro-
cesses which include cell cycle progression, survival, glucose
metabolism, DNA repair and chromatin re-modelling.4,10 Fur-
thermore, HSF1 supports malignant progression by promot-
ing tumour invasion, angiogenesis and metastasis,11–13 which
includes the re-programming of stromal cells within the tu-
mour microenvironment.14
A key feature in the HSF1-mediated response to proteotoxic
stress is the upregulation of heat shock proteins (HSPs) in-
cluding HSP72 and HSP90.15 The HSPs are chaperone pro-
teins critical for proper protein folding, preventing self-associ-
ation, maintaining active multi-protein complexes and
directing misfolded proteins to be degraded.16,17 In addition,
depletion of HSF1 destabilizes ribosomal subunit proteins,
which reveals a link between cellular chaperoning and trans-
lational capacity.18 Importantly there is a positive correlation
between increased expression of nuclear (activated) HSF1 and
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HSPs and poor patient outcome, including poor prognosis in
many breast cancers.6,9
Taken together, the above results support the exciting pos-
sibility that inhibiting the HSF1-stress pathway could repre-
sent a novel therapeutic strategy that would deliver strong se-
lective effects against cancer cells. This is supported by target
validation studies using knockdown of HSF1 by genetic
means.4,19
A number of structurally diverse compounds have been
reported to act as inhibitors of HSF1 or the HSF1-stress path-
way, via a variety of proposed mechanisms of action.8,20
However, HSF1 is a ligand-less transcription factor with poor
predicted druggability and as such is difficult to inhibit di-
rectly using a small molecule approach. Consequently, we de-
cided to conduct an unbiased cell-based phenotypic screen to
identify inhibitors of the HSF1-stress pathway.
2. Results and discussion
2.1. Hit identification
To discover inhibitors of the HSF1-stress pathway, we
employed an automated cellular imaging and analysis
method (ArrayScan™) that quantifies the ability of a com-
pound to suppress the expression of the HSF1-mediated in-
ducible HSP70 isoform, HSP72. Cancer cells were treated
with 17-allylamino-17-demethyoxygeldanamycin (17-AAG) an
HSP90 inhibitor known to stimulate an HSF1-mediated re-
sponse21,22 and compounds that blocked expression of
HSP72 were thereby defined as inhibitors of the HSF1-stress
pathway.
Approximately 200 000 small molecules (consisting of
35 000 kinase-directed compounds and a diversity set of
165 000 compounds from the AstraZeneca collection) were
screened using this approach in the U2OS human osteosar-
coma tumour cell line. One of the hits selected for progres-
sion was the 4,6-disubstituted pyrimidine 1 which, following
re-synthesis, was confirmed as active with a cellular IC50
value of 2.00 μM for HSF1-stress pathway inhibition (Fig. 1).
In-house data revealed that 4,6-pyrimidine 1 also pos-
sessed modest CDK2 activity with an IC50 value of 1.14 μM in
a biochemical assay, though it was unclear at this stage
whether this kinase activity was important for the observed
HSF1 cellular phenotype.
Prior to investigating the structure activity relationship
(SAR) it was necessary to improve the solubility of alcohol 1.
To achieve this, the phenethyl alcohol chain was replaced
with an oxygen-linked dimethylamino side chain to give 2.
This modification retained potency in the HSF1-stress path-
way assay (1.35 μM), but was less potent against CDK2 (20.0
μM). Preliminary explorations of the SAR (Table 1) were initi-
ated to assess the effect that structural changes would have
on both the HSF1-stress pathway activity and biochemical
CDK2 activity, using the dimethylamino-containing com-
pound 2 as a starting point. Substitution of the phenyl ring
for a 2-pyridine ring (3) afforded a compound which was ap-
proximately 15-fold more potent in the HSF1-stress pathway
assay and 35-fold more active against CDK2 when compared
with phenyl compound 2. To facilitate progression of this se-
ries we attempted to obtain a crystal structure of 2-pyridine 3
bound to CDK2, but without success. Fortunately, adding an
extra methylene to the side chain (4) afforded an analogue
with a modest improvement in affinity for CDK2 which could
be used to generate a crystal structure (Fig. 2). The CDK2
used for crystallisation was expressed, purified and
crystallised in the absence of cyclin. Analysis of the crystal
structure revealed that the pyrimidine N1 and 6-NH group
form a typical hydrogen bond pair interaction with Leu83
(ref. 23) in the hinge region of CDK2. The benzimidazole N3
is observed to form a water-mediated hydrogen bond to the
side-chain of Asp145 and the ether oxygen is involved in a
water-mediated hydrogen bond to Asp86. The benzimidazole
ring system stacks between three lipophilic residues Phe80,
Val18 and Ala144.
With the crystal structure in hand, we were in a position
to explore the hypothesis that inhibition of CDK2 forms the
basis of the observed HSF1-stress pathway inhibition. Using
single structural changes with respect to 4,6-disubstituted py-
rimidine 3 and comparing the activity of the compounds gen-
erated we aimed to distinguish which features of the SAR
gave potency and selectivity for each assay.
2.2. Rational analogue design
We began by examining the role of the central pyrimidine
ring. Introduction of a methyl group at C-5 to afford pyrimi-
dine (5) was predicted to cause a steric clash with the other
substituents on the ring, disfavouring the planar binding
conformation and disrupting CDK2 binding. In both the
CDK2 and the HSF1-stress pathway assays a large drop in ac-
tivity was measured (>100- and >300-fold respectively). Next,
we examined the contribution of the benzimidazole head
group. Compounds were designed that would interrogate
whether the water-mediated hydrogen bond to Asp145, and
the ability of the group to be involved in π-stacking, were im-
portant for CDK2 activity and whether this would also impact
the HSF1-stress pathway activity.
Exploration commenced with imidazole 6, a truncated
compound that is able to form the required hydrogen bond,
but cannot be involved in π-stacking. A drop in potency was
observed with imidazole 6 in the HSF1-stress pathway assay
(77-fold) and to a lesser extent the CDK2 biochemical assay
(12-fold). Indazole 7 and indole 8 are unable to form a
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hydrogen bond with Asp145 and showed a drop in potency in
both assays. The corresponding quinoline 9 is capable of
forming a weak hydrogen bond whilst maintaining the ability
for π-stacking. However, this compound was also less potent
(∼200 fold for the HSF1-stress pathway assay and inactive in
the CDK2 assay) as compared to benzimidazole 3.
7-Azabenzimidazole 10 has the potential for H-bond forma-
tion, but a polar group has been introduced onto the aro-
matic ring and a loss in potency is observed in both assays
compared to benzimidazole 3. Surprisingly the introduction
of a nitrogen atom at C-4 of the benzimidazole ring, to afford
4-azabenzimidazole 11 led to a 3-fold increase in HSF1-stress
pathway inhibition and a 5-fold improvement in CDK2 inhi-
bition compared with benzimidazole 3. Finally, the co-crystal
structure of 4 with CDK2 suggested a small lipophilic substit-
uent at C-6 of the benzimidazole could be accommodated.
Table 1 Investigation of SAR surrounding 4,6-pyrimidines for HSF1-stress pathway and CDK2 assays
general structure for Table 1
Compound R1 R2 R3 HSF1 IC50
a (μM) CDK2 IC50
a (μM)
3 H 0.080 0.580
4 H 0.165 0.368
5 Me >30 65.8
6 H 6.15 7.10
7 H >30 29.8
8 H 2.33 4.43
9 H 17.6 >100
10 H 0.760 1.60
11 H 0.028 0.161
12 H 0.039 0.121
13 H 4.28 4.61
14 H H 0.842 0.059
15 H 0.198 0.690
16 H 0.055 0.535
17 H 0.045 0.492
18 H 0.295 0.554
19 H 0.057 0.358
20 H 0.884 1.24
21 H 0.450 0.643
22 H 1.38 0.836
23 H 0.610 0.776
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This hypothesis was confirmed with 6-methylbenzimidazole
12 and which showed a small increase in potency in both as-
says. In contrast, substitution at C-2 of the benzimidazole
was predicted to create a steric clash with the phenylalanine
gatekeeper of CDK2. This hypothesis was confirmed with
2-methylbenzimidazole 13, where a >7-fold loss in activity
was observed in both assays. In summary, modifications to
the benzimidazole ring showed that the 4-azabenzimidazole
was the most potent substituent at this position.
In the CDK2 co-crystal structure the amine tail resides in
a solvent channel. Cho et al. have demonstrated that bulky
amine groups at the periphery of the ATP binding site clash
with Lys89 of CDK2 and help improve selectivity towards
other kinase family members, such as CDK4 and CDK6.24
Therefore, in an attempt to examine whether CDK2 and
HSF1-stress pathway inhibition correlated, several analogues
were synthesised to explore the impact of variation at this
vector on CDK2 and HSF1-stress pathway activity.
Removal of the solvent channel substituent to afford pyri-
dine 14 showed a 10-fold increase in CDK2 activity with a
concomitant 10-fold loss of HSF1-stress pathway activity. To
probe whether the water-mediated hydrogen bond by the
oxygen-linked tail (observed in the co-crystal structure) was
essential, propyl-linked 15 was synthesised. However, little
change in potency was observed against either CDK2 or the
HSF1-stress pathway. Compounds 16–23 were synthesised to
investigate the effects on activity in both assays of increased
bulk around the amine tail. Both of the N-methylpyrrolidine
enantiomers (16 and 17) and the piperidine 19 displayed
modest 2-fold improvement in HSF1-stress pathway activity
but maintained similar potency against CDK2, compared
with the dimethylamino-solubilising tail 3.
2.3. Combining selected SAR
To assess whether the SAR features described above were ad-
ditive, the combination compounds 24 and 25 were
synthesised (Table 2).
Modification of the benzimidazole head group to afford a
4-azabenzimidazole in combination with selected cyclised
amine tails afforded two potent compounds, methyl-
pyrrolidine 24 and piperidine 25. Both analogues displayed
excellent activity in the HSF1-stress pathway assay (14 nM
and 15 nM respectively). Piperidine 25 was also our most ac-
tive CDK2 inhibitor (55 nM).
3. Discussion
With a range of pyrimidines in hand, we were able to analyse
the role of CDK2 inhibition in the HSF1 cellular phenotype.
Despite a variety of structural changes we observed some cor-
relation (R2 = 0.56) between CDK2 activity and HSF1 pathway
inhibition (Fig. 3). However, there were analogues which
seemed to indicate that CDK2 activity and HSF1 activity could
be uncoupled, for example phenyl pyrimidine 2 displays a 15-
fold difference in activity between the CDK2 and HSF1-stress
pathway assays. This suggests that either inhibition of CDK2
activity is not the key determinant of HSF1-stress pathway an-
tagonism, or alternatively that it is necessary to inhibit multi-
ple kinases (polypharmacology) to observe HSF1-stress path-
way inhibition.25
It is well established that there is a high level of sequence
homology, particularly at the catalytic binding site, between
members of the CDK protein family.26,27 Consequently,
Fig. 2 X-ray co-crystal structure of 4 bound to CDK2. Measurements
in Å. PDB ID 4BZD.
Fig. 3 Graph showing the correlation between HSF1 pathway
inhibition (ArrayScan™) pIC50 and CDK2 inhibition pIC50 for
compounds in this paper.
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developing selective inhibitors within this protein family is
challenging.26 If CDK2 is not responsible or is only partially
responsible for the observed HSF1-stress pathway inhibition,
we hypothesised that the direct target must share consider-
able structural similarity in the binding site to CDK2.
Therefore 4,6-pyrimidine 3 was submitted to a EMD Milli-
pore CDK panel to assess potency across the selected CDK
family members (Table 3). Modest activity was observed
against several CDKs; however, this compound was highly po-
tent against CDK9 (14 nM). Following this result, we ex-
panded our screening and several 4,6-disubstituted pyrimi-
dines were also selected for testing against CDK9. In each
case the compounds were potent against CDK9 (Table 4), and
with the exception of imidazole 6, activity in the HSF1 assay
and CDK9 assay were comparable. Although 6 is the least po-
tent compound in the CDK9 assay the fall off in cellular po-
tency is greater than expected.
CDK9 is known to be a component of the positive
transcription elongation factor b (P-TEFb).28,29 This en-
zyme is vital as it stimulates the transcription elongation
of most protein coding genes (which include key develop-
mental and stimulus responsive genes) by phosphorylation
of the carboxy-terminal domain of RNA polymerase II
(RNAPII).30,31 Inhibition of CDK9 has been shown to have
particular impact on the levels of mRNAs with short half-
lives, typified by transcriptionally inducible mRNAs.32 It
has also been demonstrated that P-TEFb associates with
HSF1 and plays a functional role in the stress-induced ex-
pression of HSP72.33
Indeed, Acquaviva et al. recently published a screen of
drugs and late stage compounds to discover HSF1 tran-
scription inhibitors (defined by the ability of a compound
to block induction of HSP72 following treatment with an
HSP90 inhibitor, ganetespib).34 Amongst the compounds
they identified was SNS-032 26, a known inhibitor of CDK2,
CDK7 and CDK9,35–37 which is consistent with the apparent
role of CDK9 in the HSF1 inhibition phenotype. The struc-
ture of SNS-032 26 derives from a completely different
chemotype to our 4,6-pyrimidine series; therefore it is less
likely that both compounds hit a large number of similar
protein targets.38,39 However, to increase confidence in the
role of CDK9 inhibition in our HSF1 pathway inhibition
phenotype, we purchased a second structurally distinct
CDK9 inhibitor, dinaciclib 27.40,41 In our hands, SNS-032 26
and dinaciclib 27 displayed CDK9 inhibition values of 6
and 4 nM respectively. Both published CDK9 inhibitors and
our optimised 4,6-pyrimidine 25 (CDK9 IC50 = 3 nM) were
then submitted to a U2OS cell-ELISA assay, which as with
the ArrayScan™ assay format, quantifies the ability of a com-
pound to block the induction of HSP72 expression upon cell
treatment with 17-AAG. As illustrated in Fig. 4, all three potent
CDK9 inhibitors, from distinct chemotypes, are effective inhibi-
tors of the HSF1 pathway. In addition, when these compounds
were tested in a sulforhodamine B (SRB) cellular growth inhibi-
tion assay as single agents, all three were observed to potently ab-
rogate cell growth.
Table 3 The activity of compound 3 in a CDK family screening panela
CDK1/cyclin B CDK2/cyclin E CDK3/cyclin E CDK5/p35 CDK6/cyclin D3 CDK7/cyclin H/MAT1 CDK9/cyclin T1
IC50 (nM) 1800 2800 3500 610 1300 1100 14
a Data obtained from EMD Millipore screening panel (N = 1), since carrying out this screen this CDK assay is now run by Eurofins (http://www.
eurofins.com/en.aspx). For assay conditions see ESI.










3 0.080 0.580 14
6 6.15 7.10 88
17 0.045 0.492 8
19 0.057 0.358 8
21 0.450 0.643 22
a Potency data are reported as the average of two determinations.
b Data obtained from EMD Millipore screening panel (N = 1), since
carrying out this screen this CDK assay is now run by Eurofins
(http://www.eurofins.com/en.aspx). For assay conditions see ESI.
Fig. 4 Published CDK9 inhibitors SNS-032 and dinaciclib. Results from
cell-ELISA assay for HSF1-mediated HSP72 induction inhibition, CDK9
data from Caliper® biochemical assay and sulforhodamine B (SRB) cell
growth inhibition assay. All potency data are reported as the average
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4. Conclusions
A high-throughput phenotypic screen was conducted to find
inhibitors of the HSF1-stress pathway in cancer cells and a
hit compound based on a di-substituted 4,6-pyrimidine scaf-
fold was discovered. This compound was known to exhibit
modest CDK2 activity (1.14 μM). Through the application of
SAR and rational design against a CDK2 co-crystal structure,
we demonstrated that although there was some correlation
between HSF1-stress pathway inhibition and CDK2 inhibi-
tion, it was possible to generate analogues where the two
measured activities were uncoupled.
Owing to the high homology between the active sites of
the CDK family members, 4,6-pyrimidine 3 was screened in a
CDK panel and found to be a highly potent inhibitor of
CDK9. To test the hypothesis that CDK9 inhibition is in-
volved in HSF1-stress pathway inhibition we purchased two
validated CDK9 inhibitors with entirely distinct chemical
structures and submitted them to an assay that quantifies
HSF1-stress pathway inhibition. Both validated CDK9 inhibi-
tors were potent inhibitors of the HSF1-stress pathway. The
rational design of highly selective inhibitors to investigate
the function and synergism of different CDKs is extremely
challenging. More work is needed to confirm CDK9 as the
key molecular target that delivers the HSF1-stress pathway in-
hibition phenotype and to establish whether kinase poly-
pharmacology is also required. The 4,6-pyrimidine 25 is a use-
ful addition as a structurally distinct in vitro chemical tool to
study the role of CDK9 inhibition and HSF1-stress pathway
inhibition. The broader kinase selectivity profile of 4,6-
pyrimidine 25 and the effect on the HSF1 pathway of a num-
ber of CDK9 inhibitors, possessing different kinase selectivity
profiles, are currently under investigation (a table showing
some CDK selectivity data can be found in the ESI‡).
Whilst the disubstituted 4,6-pyrimidine series has shown
potency against CDK9 and the HSF1-stress pathway, this se-
ries showed high clearance in mouse pharmacokinetic experi-
ments making these compounds unsuitable for progression
into animal models. However, other chemical series devel-
oped as inhibitors of the HSF1-stress pathway have shown
more promise and will be published in due course.
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